WEBVTT

1
00:00:00.000 --> 00:00:04.600
>>GERRY: TIME NOW FOR THEBUSINESS OF HEALTH, BROUGHT TOYOU BY HENDRICKS REGIONALHEALTH.

2
00:00:04.600 --> 00:00:11.440
BIONODE IS A PURDUE-AFFILIATEDSTARTUP THAT IS SHEDDING LIGHTON A NEW TREATMENT FOR GLAUCOMA,THE SECOND LEADING CAUSE OF

3
00:00:11.440 --> 00:00:18.150
BLINDNESS.INSIDE INDIANA BUSINESS REPORTERKYLIE VELETA IS IN FOR BARBLEWIS WITH MORE.

4
00:00:18.150 --> 00:00:23.760
>>KYLIE: CURRENT TREATMENTS FORGLAUCOMA JUST SLOW ITS>F)PROGRESSION.PATIENTS USUALLY GO BLIND WITHIN

5
00:00:23.760 --> 00:00:30.360
15 TO 20 YEARS.HOWEVER, USING ONLY CONTACTLENSES AND GLASSES, A PURDUEPROFESSOR HAS CREATED A

6
00:00:30.360 --> 00:00:35.370
TECHNOLOGY THAT IS ALREADYSHOWING PROMISE IN HUMANPATIENTS.JOINING ME TO TELL US ABOUT HIS

7
00:00:35.370 --> 00:00:44.380
DISCOVERY IS PURDUE PROFESSOR OFELECTRICAL AND COMPUTERENGINEERING AND BIOMEDICALENGINEERING DR. PEDRO IRAZOQUI.

8
00:00:44.380 --> 00:00:50.780
THANKS FOR COMING TODAY.>> YOU ARE WELCOME.>> LET'S START WITH THE BASES.TELL US ABOUT YOUR TECHNOLOGY IS

9
00:00:50.780 --> 00:00:58.790
HOW WE CAN UNDERSTAND HOW ITWORKS.>> IN A NUTSHELL IT'S ACONTACT LENS THAT HAS A GOLD

10
00:00:58.790 --> 00:01:07.430
TRACE EMBEDDED WITHIN THECONTACT THAT IS AN ELECTRODE SOTHE CONTACTBHçLm LENS PICKS UP TMAGNETIC FIELD AND TURNS IT INTO

11
00:01:07.430 --> 00:01:14.870
A SPECIFIC CURRENT THAT DELIVERSA VERY SPECIFIC PART OF THEOPENING THE DRAINAGE STRUCTUREALLOWING THE FLUID TO FLOW OUT

12
00:01:14.870 --> 00:01:21.820
AND THE PRESSURE TO COME DOWNAND THAT'S THE TREATMENT FORGLAUCOMA.>> IT REALLY IS RIFFS --

13
00:01:21.820 --> 00:01:27.750
RELIEVES THE PRESSURE THATCAUSES GLAUCOMA.>> WE SEE A REDUCTION OF40 PERCENT IN FIVE MINUTES.

14
00:01:27.750 --> 00:01:35.360
IT'S WHAT YOU SEE WITH EYEDROPSWHICH IS THE STANDARD OF CARETHAT YOU WOULD SEE IT IN MONTHSAND WE CAN DO IT IN MINUTES AND

15
00:01:35.360 --> 00:01:40.900
MAINTAIN THAT.>> YOU'VE DONE A SMALL TRIALAND TELL US ABOUT THE RESULTS.>> A COLLEAGUE OF OURS IN

16
00:01:40.900 --> 00:01:48.940
SPAIN IS AN OPHTHALMOLOGIST ANDHE HAS TRIED THIS OUT ON ANUMBER OF PATIENTS ON WHAT HEHAS FOUND IS EXACTLY THAT, THAT

17
00:01:48.940 --> 00:01:55.980
WE EXPECTED FROM THE WORK WE DIDTHAT WE WOULD SEE THIS DROP ANDHE'S DONE THIS IN HUMANS ANDPATIENTS WITH GLAUCOMA IN SOME

18
00:01:55.980 --> 00:02:04.990
PATIENTS HAVE BEEN THROUGH DROPSTHAT HAVE BEEN THROUGH EYESURGERY AND HAD SHOWN SORE BLOODPROCEDURES DONE AND EXACTS DID

19
00:02:04.990 --> 00:02:13.330
ALL THEIR OPTIONS AND EVEN INTHOSE PATIENTS WE TAKE THEIR EYEPRESSURE FROM THE DANGEROUS ZONEIN THE 20-20 SOME MILLIMETERS OF

20
00:02:13.330 --> 00:02:18.440
MERCURY DOWNp;F[u BELOW '13-'14MILLIMETERS IN FIVE MINUTES ANDKEEP IT THERE.jU$E

21
00:02:18.440 --> 00:02:25.410
>> DOESN'TW>VSiPROGRESSION OF GOD, OR IS IT ACURE?>> WE ARE HOPING IT]!jOç IS A.

22
00:02:25.410 --> 00:02:33.020
GLAUCOMA IS THE PRESSURE BUILDUP IN THE ANTERIOR CHAMBER OFTHE EYE GETS TRANSMITTED TO THEINTERIOR OF THE EYEWEAR PRESSES

23
00:02:33.020 --> 00:02:41.290
ON THE OPTIC NERVE AND THETHEORY IS THAT PRESSURE CAUSESAND SO THE BLINDNESS IS A RESULTOF THAT PRESSURE.

24
00:02:41.290 --> 00:02:46.970
IF WE ALLEVIATE THE PRESSUREWHICH WE CAN DO AND MAINTAINWITH THIS THERAPY THEN THENEURONS WILL NOT DIE.

25
00:02:46.970 --> 00:02:56.780
THE BLINDNESS WON'T COME IN.Eñ>> THAT'S RIGHTg>> YOU HAVE A CLINICAL TRIAL

26
00:02:56.780 --> 00:03:01.980
COMING UP THAT WILL GIVE YOUMORE INF[MAT>> THE QUESTIONS THAT ON THISNARE IF. WE DO THIS, SO IF YOU

27
00:03:01.980 --> 00:03:09.120
TAKE DROPS RIGHT NOW, THEY LASTFOR A PERIOD OF TIME, BUTEVENTUALLY YOU STOP RESPONDINGLIKE WITH ANY PHARMACEUTICAL

28
00:03:09.120 --> 00:03:14.990
THERAPY.IF YOU HAVEgAÑdñ LASER EYE SURGTLASTS FOR A WHILE BUT AFTER AWHILE THEY BECOME OCCLUDED AND

29
00:03:14.990 --> 00:03:20.370
ONLY SO MANY TIMES YOU CAN DOSURGERY.WITH OUR DEVICES IT WORKSREALLY, REALLY WELL AND MUCH

30
00:03:20.370 --> 00:03:26.940
QUICKER AND DOES NOT HAVE SIDEEFFECTS, BUT HOW LONG WILL THEEFFECT LAST AND THAT'S WHAT WENEED TO ANSWER WITH A CLINICAL

31
00:03:26.940 --> 00:03:32.480
TRIAL ANDBñ)THAT'S WHAT WE ARElGsHOPING TO DO NEXT.>> WHAT ARE THE NEXT STEPS FOR

32
00:03:32.480 --> 00:03:40.020
BRINGING YOUR TECHNOLOGY TOMARKET?>> THE CLINICAL TRIAL ANDAPPROVAL IN THE UNITED STATES

33
00:03:40.020 --> 00:03:49.900
AND GETTING IT INTO THE HANDS OFATOMIC TRYSTS AND THE DEVICE ISINVASIVE ENOUGH THAT OPTOMETRISTCAN PRESCRIBE IT AND TRYING TO

34
00:03:49.900 --> 00:03:50.900
SEE HOW MANY PATIENTS WE CAN GET